Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pVGI.1
- Development stage
- Discontinued
- Lead developer
- Valentis
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Therapies
- Administration
- Intramyocardial
01
Overview
pVGI.1 is a recombinant plasmid DNA gene therapy designed to encode the human Vascular Endothelial Growth Factor C (VEGF-C), also referred to as VEGF-2. Developed primarily for the treatment of severe angina pectoris and myocardial ischemia, the drug is intended to stimulate therapeutic angiogenesis—the growth of new blood vessels—to improve blood flow to ischemic heart tissue. The plasmid is typically delivered via direct intramyocardial injection using specialized catheter systems like the Stiletto™ catheter. While VEGF-C is best known for its role in lymphangiogenesis via the VEGFR-3 receptor, it also possesses angiogenic activity through its interaction with VEGFR-2, making it a candidate for treating coronary artery disease.
- Other names
- VEGF-2 gene therapyVEGF2 gene therapyVEGF 2 gene therapyVEGF-C gene therapyPlasmid VEGF-CpVGI.1-VEGF-C
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR3 (Vascular endothelial growth factor receptor 3)
Beyond the preview
Go deeper on pVGI.1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pVGI.1.